tetano
Editor, Senior Moderator
Int J Mol Sci
. 2022 Feb 6;23(3):1850.
doi: 10.3390/ijms23031850.
A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
Julie Zimmermann[SUP] 1 [/SUP], Signe Tandrup Schmidt[SUP] 1 [/SUP], Ramona Trebbien[SUP] 2 [/SUP], Rebecca Jane Cox[SUP] 3 [/SUP], Fan Zhou[SUP] 3 [/SUP], Frank Follmann[SUP] 1 [/SUP], Gabriel Kristian Pedersen[SUP] 1 [/SUP], Dennis Christensen[SUP] 1 [/SUP]
Affiliations
Abstract
The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to vaccine approval. The liposomal vaccine adjuvant CAF[SUP]®[/SUP]09b contains the TLR3 agonist polyinosinic
olycytidylic acid, which induces a type I interferon (IFN-I) response and an antiviral state in the affected tissues. When testing CAF09b liposomes as a potential pan-viral prophylaxis, we observed that intranasal administration of CAF09b liposomes to mice resulted in an influx of innate immune cells into the nose and lungs and upregulation of IFN-I-related gene expression. When CAF09b liposomes were administered prior to challenge with mouse-adapted influenza A/Puerto Rico/8/1934 virus, it protected from severe disease, although the virus was still detectable in the lungs. However, when CAF09b liposomes were administered after influenza challenge, the mice had a similar disease course to controls. In conclusion, CAF09b may be a suitable candidate as a pan-viral prophylactic treatment for epidemic viruses, but must be administered prior to virus exposure to be effective.
Keywords: influenza virus; liposomal adjuvant; type I IFN; virus prophylactic (treatment).
. 2022 Feb 6;23(3):1850.
doi: 10.3390/ijms23031850.
A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
Julie Zimmermann[SUP] 1 [/SUP], Signe Tandrup Schmidt[SUP] 1 [/SUP], Ramona Trebbien[SUP] 2 [/SUP], Rebecca Jane Cox[SUP] 3 [/SUP], Fan Zhou[SUP] 3 [/SUP], Frank Follmann[SUP] 1 [/SUP], Gabriel Kristian Pedersen[SUP] 1 [/SUP], Dennis Christensen[SUP] 1 [/SUP]
Affiliations
- PMID: 35163772
- DOI: 10.3390/ijms23031850
Abstract
The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to vaccine approval. The liposomal vaccine adjuvant CAF[SUP]®[/SUP]09b contains the TLR3 agonist polyinosinic
olycytidylic acid, which induces a type I interferon (IFN-I) response and an antiviral state in the affected tissues. When testing CAF09b liposomes as a potential pan-viral prophylaxis, we observed that intranasal administration of CAF09b liposomes to mice resulted in an influx of innate immune cells into the nose and lungs and upregulation of IFN-I-related gene expression. When CAF09b liposomes were administered prior to challenge with mouse-adapted influenza A/Puerto Rico/8/1934 virus, it protected from severe disease, although the virus was still detectable in the lungs. However, when CAF09b liposomes were administered after influenza challenge, the mice had a similar disease course to controls. In conclusion, CAF09b may be a suitable candidate as a pan-viral prophylactic treatment for epidemic viruses, but must be administered prior to virus exposure to be effective.Keywords: influenza virus; liposomal adjuvant; type I IFN; virus prophylactic (treatment).